Analyst firms · Morgan Stanley · BMY
Morgan Stanley BMY price target and rating history
Bristol-Myers Squibb Company (BMY) · Health Care
Morgan Stanley rates Bristol-Myers Squibb Company (BMY) Underweight with a $64 price target, as of its latest action on Apr 6, 2022. It has published 3 rating actions on BMY since July 2021, including 0 upgrades and 0 downgrades. Across 7 firms with a BMY price target in the last 12 months, the median target is $62.
- Current rating
- Underweight
- Price target
- $64
- Median target, all firms
- $62
- Actions on BMY
- 3
Morgan Stanley price target on BMY
Every Morgan Stanley rating on BMY
- Apr 6, 2022
- Oct 12, 2021
- Jul 29, 2021
How other firms rate BMY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Market Perform | $59 | Oct 5, 2026 |
| Argus Research | Buy | $75 | Aug 5, 2026 |
| RBC Capital Markets | Sector Perform | $60 | Feb 25, 2026 |
| Barclays | Overweight | $75 | Feb 20, 2026 |
| UBS | Buy | $65 | Jan 7, 2026 |
| BofA Securities | Buy | $61 | Dec 15, 2025 |
| Guggenheim | Buy | $62 | Dec 12, 2025 |
Questions about Morgan Stanley and BMY
- What is Morgan Stanley's price target for BMY?
- Morgan Stanley's latest stated price target for Bristol-Myers Squibb Company (BMY) is $64, from its action on Apr 6, 2022.
- What is Morgan Stanley's rating on BMY?
- Morgan Stanley rates BMY Underweight, a bearish rating, as of Apr 6, 2022.
- When did Morgan Stanley last change its view on BMY?
- On Apr 6, 2022, Morgan Stanley resumes coverage at Underweight, price target $64.
- How does Morgan Stanley's BMY target compare with other analysts?
- Across 7 firms with a BMY price target in the last 12 months, the median target is $62.
More BMY rating histories
All Morgan Stanley ratingsBMY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.